Kansas · J0702

Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg in Kansas

Kansas Medicare Avg
$4.68
4% below national avg
National Medicare Avg
$4.88
All states combined
Billed Charge (KS)
$15.35
What providers submit
Est. Commercial (KS)
$13.57
National avg: $14.56
Est. Cash / Self-Pay (KS)
$9.11
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

19.4K
Services in KS
191
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Kansas

Provider Medicare Services
Meister, Brad M.D. $4.80 1.8K

Kansas Pricing in Context

In Kansas, CPT code J0702 (Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg) carries an average Medicare payment of $4.68 — 4% below the national benchmark of $4.88. 191 providers across the state submitted claims for this procedure in 2023, performing 19.4K total services. Individual payments in KS ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Kansas is $15.35, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Kansas sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Kansas lands near $13.57, with self-pay cash prices typically around $9.11. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg cost in Kansas?

The average Medicare payment for Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg in Kansas is $4.68, which is 4% below the national average of $4.88. Providers in KS typically bill $15.35 for this procedure.

What does Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg cost with insurance in Kansas?

With commercial insurance in Kansas, Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg costs an estimated $13.57. Without insurance, the estimated cash price is $9.11. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg in Kansas?

191 providers in Kansas billed Medicare for Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg in 2023, performing 19.4K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg cheaper in Kansas than the national average?

Yes — Injection, Betamethasone Acetate 3 Mg And Betamethasone Sodium Phosphate 3 Mg costs 4% below the national average in Kansas. The state average Medicare payment is $4.68 compared to $4.88 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial